Kashiv BioSciences is a fully-integrated biopharmaceutical company with global R&D, clinical, regulatory, and manufacturing
capabilities. The company was originally formed as a specialty pharmaceutical business and has since transformed itself to develop
and deploy its end-to-end biosimilars platform and aggressively expand its pipeline. In the first half of 2022, Kashiv validated its
biosimilars platform after receiving FDA approvals for RELEUKO® (biosimilar to NEUPOGEN®) and FYLNETRA® (biosimilar to
We leverage our expertise in large and complex small molecules to continue building and advancing a differentiated pipeline of biosimilars, 505(b)(2), complex peptide generics, and mRNA therapies. We seek to commercialize our programs via strategic partnerships to maintain a deep focus on R&D and manufacturing.